On July 29, Glaukos rose 5.05% in after-hours trading, trading at 170.25 USD/share, with turnover of $4.76 million. The after-hours gain was driven by the convergence of a key pipeline milestone and quarterly earnings catalyst.

On July 27, Glaukos announced the completion of patient enrollment for its US 510(k) pivotal study evaluating the Preserflo MicroShunt in adult patients with primary open-angle glaucoma who failed previous medical and surgical treatment. The study enrolled its target of at least 110 patients at clinical sites in the US and Canada, marking a critical step toward potential commercialization. Additionally, market consensus had projected Q2 revenue of approximately $151 million, representing 30.68% year-over-year growth, extending the strong momentum from Q1 where revenue of $150.6 million and adjusted EPS of -$0.18 both significantly beat estimates.

On the institutional front, Truist raised its price target to $180 from $160 while maintaining a Buy rating, and Needham has issued multiple target increases. While UBS recently downgraded the stock to Neutral, the FactSet consensus mean target of $163.85 reflects a predominantly bullish outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)